OLIVO Study

Phase 1

• Conditions: SARS-CoV2; SARS Virus; Disease Prevention; Coronaviridae Infections; Nidovirales Infections; Coronavirus Infections; Prophylaxis of SARS-CoV-2 infection; COVID-19; Betacoronavirus

• Registration Number: RPCEC00000337
• Lead Sponsor: Center for Genetic Engineering and Biotechnology (CIGB), in Havana

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-10-01
• Study Completion: 2020-11-21
• Results First Posted: 2020-12-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1) Individuals aged = 19 years.
2) Voluntariness of the subject by signing the informed consent.

Exclusion Criteria

1) Virological diagnosis by RT-PCR of infection to SARS-CoV-2.
2) Treatment with immunosuppressants in the last month prior to inclusion.
3) Ongoing treatment, for any reason, with any IFN formulation.
4) Acute illnesses in the last 30 days.
5) Use of any other medication intranasally.
6) Subjects who underwent tonsillectomy.
7) History of allergic rhinitis and recurrent episodes of nasal bleeding.
8) Active chronic asthma.
9) Patients with myasthenia gravis.
10) Chronic, autoimmune or endocrine-metabolic diseases decompensated at the time of inclusion.
11) Administration of an investigational drug in the 30 days prior to inclusion in the study.
12) Known hypersensitivity to thiomersal and any of the components of the formulation under study.
13) Pregnancy or breastfeeding.
14) Obvious mental incapacity to issue consent and act accordingly with the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified